17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial
- PMID: 25979614
- DOI: 10.1016/j.ajog.2015.05.009
17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial
Abstract
Objective: Preterm rupture of membranes (PROM) is associated with an increased risk of preterm birth and neonatal morbidity. Prophylactic 17-hydroxyprogesterone caproate (17OHP-C) reduces the risk of preterm birth in some women who are at risk for preterm birth. We sought to test whether 17OHP-C would prolong pregnancy or improve perinatal outcome when given to mothers with preterm rupture of the membranes.
Study design: This is a multicenter, double-blind, placebo-controlled, randomized clinical trial. The study included singleton pregnancies with gestational ages from 23(0/7) to 30(6/7) weeks at enrollment, documented PROM, and no contraindication to expectant management. Consenting women were assigned randomly to receive weekly intramuscular injections of 17OHP-C (250 mg) or placebo. The primary outcome was continuation of pregnancy until a favorable gestational age, which was defined as either 34(0/7) weeks of gestation or documentation of fetal lung maturity at 32(0/7) to 33(6/7) weeks of gestation. The 2 prespecified secondary outcomes were interval from randomization to delivery and composite adverse perinatal outcome. The planned sample size was 222 total women.
Results: From October 2011 to April 2014, 152 women were enrolled; 74 women were allocated randomly to 17OHP-C, and 78 were allocated randomly to placebo. The trial was stopped when results of a planned interim analysis suggested that continuation was futile. The primary outcome was achieved in 3% of the 17OHP-C group and 8% of the placebo group (P = .18). There was no significant between-group difference in the prespecified secondary outcomes, randomization-to-delivery interval (17.1 ± 16.1 vs 17.0 ± 15.8 days, respectively; P = .76) or composite adverse perinatal outcome (63% vs 61%, respectively; P = .93). No significant differences were found in other outcomes, which included rates of chorioamnionitis, postpartum endometritis, cesarean delivery, individual components of the composite outcome, or prolonged neonatal length of stay.
Conclusion: Compared with placebo, weekly 17OHP-C injections did not prolong pregnancy or reduce perinatal morbidity in patients with PROM in this trial.
Keywords: 17-hydroxyprogesterone caproate; preterm rupture of membranes; prevention of preterm birth.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.Am J Obstet Gynecol. 2015 Apr;212(4):485.e1-485.e10. doi: 10.1016/j.ajog.2014.10.1097. Epub 2014 Oct 30. Am J Obstet Gynecol. 2015. PMID: 25448515 Clinical Trial.
-
A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.BJOG. 2015 Jan;122(1):71-9. doi: 10.1111/1471-0528.13031. Epub 2014 Aug 27. BJOG. 2015. PMID: 25163819 Clinical Trial.
-
Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes.Am J Obstet Gynecol. 2016 Feb;214(2):287.e1-287.e5. doi: 10.1016/j.ajog.2015.09.093. Epub 2015 Oct 3. Am J Obstet Gynecol. 2016. PMID: 26435047
-
Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis.BJOG. 2015 Jan;122(1):27-37. doi: 10.1111/1471-0528.13032. Epub 2014 Aug 22. BJOG. 2015. PMID: 25145491 Free PMC article. Review.
-
17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysis.BJOG. 2016 Apr;123(5):682-90. doi: 10.1111/1471-0528.13779. Epub 2015 Dec 10. BJOG. 2016. PMID: 26663620 Free PMC article. Review.
Cited by
-
Addressing a broken drug pipeline for preterm birth: why early preterm birth is an orphan disease.Am J Obstet Gynecol. 2023 Dec;229(6):647-655. doi: 10.1016/j.ajog.2023.07.042. Epub 2023 Jul 27. Am J Obstet Gynecol. 2023. PMID: 37516401
-
Use of progesterone supplement therapy for prevention of preterm birth: review of literatures.Obstet Gynecol Sci. 2017 Sep;60(5):405-420. doi: 10.5468/ogs.2017.60.5.405. Epub 2017 Sep 18. Obstet Gynecol Sci. 2017. PMID: 28989916 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Miscellaneous